Shift Bioscience
UK - CambridgeBiotechnology
Focus: Shift Bioscience is a UK-based biotech founded in 2017 focused on small molecule therapeutics for skin care and anti-aging applications. The company is publicly listed but appears to be in early commercialization stages with minimal product revenue visibility.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
10+10 this month
Growing — net +10 jobs in 30d
16 jobs added vs 6 removed. Steady team buildout.
Should You Work at Shift Bioscience?
AI assessmentEarly-stage public biotech with promising market positioning but opaque clinical pipeline and back-office-heavy hiring that warrant skepticism about near-term career growth and scientific impact.
Why Work Here
- Early-stage public company offers equity upside potential with established public market access rather than reliance on private funding rounds.
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Shift Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.